Lowest Value Trap Pharmaceutical Preparations Stocks 2026
Safest value Pharmaceutical Preparations stocks in 2026 with the lowest Value Trap scores. Avoid value traps with CirclFi's institutional-grade multi-signal screening.
Top 10
Screened from 308 equities.
| # | Ticker | Company | Signal | QOC | Price | Trap Score |
|---|---|---|---|---|---|---|
| 1 | ASND | Ascendis Pharma A/S | 6.1 | $265.22 | 6/100 | |
| 2 | CANF | Can-Fite Biopharma Ltd | 2.4 | $3.24 | 6/100 | |
| 3 | CMMB | Chemomab Therapeutics Ltd. | 2.2 | $1.65 | 6/100 | |
| 4 | DYN | Dyne Therapeutics, Inc. | 5.0 | $23.64 | 6/100 | |
| 5 | ENLV | Enlivex Ltd. | 2.4 | $6.67 | 6/100 | |
| 6 | EPRX | Eupraxia Pharmaceuticals Inc. | 2.2 | $6.43 | 6/100 | |
| 7 | GHRS | GH Research PLC | 4.8 | $25.35 | 6/100 | |
| 8 | IDYA | IDEAYA Biosciences, Inc. | 5.5 | $36.15 | 6/100 | |
| 9 | INDV | Indivior Pharmaceuticals, Inc. | 4.1 | $40.21 | 6/100 | |
| 10 | KURA | Kura Oncology, Inc. | 6.4 | $10.91 | 6/100 | |
| 11 | L••• | Lipocine ••••• | •.• | $•••.•• | ••.•% | |
| 12 | L••• | Lexicon ••••• | •.• | $•••.•• | ••.•% | |
| 13 | M••• | Monopar ••••• | •.• | $•••.•• | ••.•% | |
| 14 | N••• | Neuphoria ••••• | •.• | $•••.•• | ••.•% | |
| 15 | N••• | Nurix ••••• | •.• | $•••.•• | ••.•% | |
| 16 | N••• | Novo ••••• | •.• | $•••.•• | ••.•% | |
| 17 | O••• | BeOne ••••• | •.• | $•••.•• | ••.•% | |
| 18 | P••• | Protagonist ••••• | •.• | $•••.•• | ••.•% | |
| 19 | S••• | Silence ••••• | •.• | $•••.•• | ••.•% | |
| 20 | S••• | ARS ••••• | •.• | $•••.•• | ••.•% |
You’re seeing 10 of 308 stocks.
Access the complete dataset with 13 institutional-grade models.
How CirclFi Ranks Pharmaceutical Preparations Stocks
CirclFi analyzes 308 Pharmaceutical Preparations stocks daily using 13 independent models processing SEC EDGAR filings, FRED macro data, and GDELT sentiment.
For Pharmaceutical Preparations stocks, CirclFi adjusts sector-relative benchmarks — comparing margins, capital intensity, and growth rates against Pharmaceutical Preparations industry medians.
Profitability Matrix
ROIC, Gross Margin expansion, and FCF Yield analysis.
Growth Vector
Revenue compounding vs. sector benchmarks.
Stability Index
Altman Z-Score, debt resilience, and earnings variance.
Frequently Asked Questions
What are the lowest value trap pharmaceutical preparations stocks in 2026?
CirclFi identifies the lowest value trap pharmaceutical preparations stocks 2026 using 13 institutional-grade valuation models including Bayesian DCF (10,000 Monte Carlo simulations), EPV (Greenwald framework), and EROIC Spread (McKinsey). Rankings update daily from SEC EDGAR filings. The current top-ranked stock is ASND (Ascendis Pharma A/S).
How does CirclFi rank Pharmaceutical Preparations stocks?
Stocks are ranked by Trap Score derived from CirclFi's proprietary models. Each model independently processes SEC EDGAR financial data (700+ XBRL tags), FRED macroeconomic indicators, and GDELT news sentiment to produce confidence-weighted fair value estimates. The ranking methodology combines multiple valuation approaches — intrinsic, relative, scenario, and ensemble — for maximum robustness.
How often is the lowest value trap pharmaceutical preparations stocks 2026 list updated?
This list is recalculated daily after US market close. Every stock is re-valued through all 13 models using the latest SEC EDGAR filings, market prices, and FRED macroeconomic data. Rankings can change daily as new financial data becomes available or market prices shift relative to fair value estimates.
What is the Quality of Company (QOC) score?
The QOC score is a 0-10 composite rating derived from 32 fundamental signals across four pillars: profitability (ROE, ROIC, margins), growth (revenue CAGR, earnings acceleration), stability (earnings volatility, debt coverage), and capital efficiency (asset turnover, free cash flow yield). Higher scores indicate stronger fundamentals. Scores above 7 represent top-tier companies.
How does this list compare to other stock screeners?
Unlike simple screeners that filter by P/E or dividend yield, CirclFi runs 13 independent institutional-grade valuation models on every stock — including Bayesian DCF with Monte Carlo simulation, Greenwald EPV, and McKinsey economic profit frameworks. Each stock receives over 76,000 data points of analysis daily. Most retail screeners use 1-2 metrics; CirclFi uses 13 models with 32 quality signals.
Buy with Gumroad